Immunoglobulin Commissioning Update
Explore the latest updates on immunoglobulin commissioning in England by NHS England, including review of clinical guidelines, development of commissioning policies, and adherence to guidelines to ensure quality care and value. Learn about the Immunoglobulin Assessment Panel, dosing recommendations, contract management support, and potential savings opportunities.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
NHSE Commissioning update Mandy Matthews 9thDecember 2016 www.england.nhs.uk
Use of immunoglobulin in England NHS England is responsible commissioner for immunoglobulin Current forecast annual spend of approximately 150 million in England Commissioned in line with national Clinical Guidelines Inconsistent with commissioning of other high cost products NHS England Immunoglobulin project group established www.england.nhs.uk
Immunoglobulin project: Review clinical guidelines Develop NHS England commissioning policies, including: Eligibility criteria, dosing and efficacy outcomes Ensure adherence to guidelines Immunoglobulin assessment panels Prior approval Improving Value opportunities: ITP dosing Contract management support www.england.nhs.uk
Review guidelines: Red indications: Current therapy Dose Clinical outcomes Clinical Reference Group (CRG) or other expert group involvement Develop into routinely commissioned policy position www.england.nhs.uk
Review guidelines: Blue and grey indications: Current therapy Dose Clinical outcomes CRG or other expert group involvement Consider within NHS England policy proposition process Prioritisation www.england.nhs.uk
Adherence to guidelines: Role of the Immunoglobulin Assessment Panel (IAP): Survey Sharing best practice Audit Prior approval system: Pilot MDSAS database On-hold until commissioning criteria agreed All use to be approved via the database www.england.nhs.uk
Improving Value opportunities: Dosing in ITP: recommended at 1g/kg Previous audit suggests significant use of higher dose Analysis of the database for use in 15/16: Potential savings of 2 million www.england.nhs.uk
Contract management support: All use of immunoglobulin to be recorded on database Risk of non-reimbursement if not recorded Recording of clinical outcomes Standard criteria Resources to support commissioners to ensure a consistent approach with trusts www.england.nhs.uk
